A Phase 2 interventional study of Metronidazole and Metronidazole-DRF1 in Clostridium Difficile Associated Diarrhea, sponsored by Dr. Reddy's Laboratories Limited. Completed at 12 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-06-07.
Sponsored by Dr. Reddy's Laboratories Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Diarrhea with a site in India — none open to participants now, 1 under way, none of them phase 3. Diarrhea · India.
Among the 42 studies in Diarrhea with a site in India, this one is the 39th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2012, is one of 7 in phase 2, and was the 26th registered.
879 studies on the registry are indexed under Diarrhea; 78 are open to participants now.
Browse Diarrhea studies →None of the 42 studies in Diarrhea with a site in India is open now. The open studies under Diarrhea, anywhere →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 11 · Phase 4 3
First in 1998; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 918 across the 40 interventional studies, 12,898 across the 2 observational. Of the 38 that completed or were terminated, 3 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 42 have an industry lead sponsor. The 10 most frequent:
Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.
Dr. Reddy's Laboratories Limited has 1 study filed under Diarrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Diarrhea with a site in India that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06168097Asian Institute of Gastroenterology, IndiaThe Use of MicroRNAs Dysregulation as Potential Biomarkers for Effective Diagnosis of Endometriosis | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies in Diarrhea with a site in India, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Clostridium difficile bacteria can be a cause of significant diarrheal disease, particularly in people who have taken potent antibiotics. When C. difficile multiplies within the colon, it produces two toxins that cause inflammation and resultant abdominal pain, fever and diarrhea. Current treatment of mild to moderate disease is with immediate release metronidazole, an antibiotic that kills C. difficile. Dr. Reddy's Laboratories has developed a delayed release form of metronidazole to release just before the colon to increase the concentration of antibiotic in the colon to improve the effectiveness of metronidazole treatment and potentially to allow less whole body exposure to the antibiotic.
This study will measure the amount of metronidazole in the blood and stool of patients with C. difficile associated diarrhea (CDAD) to confirm that the new formulations are releasing the antibiotic as designed, immediately before the colon.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immediate release metronidazole
Drug: Metronidazole
Modified release metronidazole (DRF1)
Drug: Metronidazole-DRF1
Modified release metronidazole (DRF2)
Drug: Metronidazole-DRF2
Immediate release metronidazole 500 mg orally three times a day for 14 days
Also known as: Flagyl®
Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
Also known as: Metronidazole
Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
Also known as: Metronidazole
Tolerability
Tolerability as assessed by physical examination, ECG, clinical laboratory tests and adverse events
Time frame: 44 Days
Pharmacokinetics
Systemic pharmacokinetics of metronidazole on Days 1 and 14. Intraluminal colonic concentration of metronidazole as reflected in excreted stool on Days 1 and 14.
Time frame: 14 Days
Clinical Cure
Response rate to treatment 2 days after completion of 14 days of metronidazole treatment with no recurrence 30 days after 14 days of metronidazole treatment (Day 44).
Time frame: 44 Days
Recurrence Rate
Recurrence defined as re-establishment of diarrhea after clinical cure.
Time frame: 44 Days
30-Day Cure Rate
Clinical cure with no recurrence and no retreatment for 30 days after 14 days of metronidazole treatment (Day 44).
Time frame: 44 Days
The record gives a start of Mar 2012, a primary completion of Feb 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metronidazole
Dr. Reddy's Laboratories Limited →